Journal article
Mirtazapine add-on therapy in the treatment of schizophrenia with atypical antipsychotics: A double-blind, randomised placebo-controlled clinical trial
M Berk, CS Gama, S Sundram, H Hustig, L Koopowitz, R D'Souza, H Malloy, C Rowland, A Monkhouse, A Monkhouse, F Bole, S Sathiyamoorthy, D Piskulic, S Dodd
Human Psychopharmacology | Published : 2009
DOI: 10.1002/hup.1017
Abstract
Objective: Schizophrenia is a multifaceted illness with positive, negative and cognitive symptom domains. Standard treatments often focus on positive symptoms and may not adequately relieve other symptoms. Previous studies have suggested a role for mirtazapine in schizophrenia, particularly in negative symptoms. This study investigates the efficacy of adding mirtazapine to treatment as usual to alleviate the negative symptoms of schizophrenia. Methods: In a 6 week, double-blind clinical trial, participants with a diagnosis of schizophrenia and currently being treated with atypical antipsychotic medication were randomised to adjunctive treatment with mirtazapine (30 mg/day) or placebo. The pr..
View full abstractGrants
Funding Acknowledgements
The authors thank Dr Ken Sharpe of the Statistical Consulting Centre, Department of Mathematics and Statistics, University of Melbourne, for analysis of the clinical trial data. They also thank Organon Australia for funding this trial.